Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction
Avainsanat
Abstrakti
Kuvaus
Between 1, July 2018 and 31, Dec 2018, consecutive individuals with metabolic syndrome hyperuricemia are candidates of the present study. After the eligible candidates sign the informed consent, they will receive blood tests with a fasting time of 8 hours at least. The investigators will randomize the study participants by pre-specified random codes with a 1:1:1 ratio to the three groups. The study medication, febuxostat or benzbromarone, will be administered orally on the next day after transthoracic echocardiography is performed. The control group will only receive dietary control. All participant will receive transthoracic echocardiography and blood tests at baseline and at 3 months. The visit will be scheduled at baseline and at the 3rd month. The blood tests include high-sensitivity C-reactive protein, high-sensitivity interleukin-1 beta, high-sensitivity interleukin-6, tumor necrosis factor alpha, Dickkopf-related protein 3, galectin-3, ST2, fibroblast growth factor 23, xanthine oxidase activity, and thioredoxin.
Päivämäärät
| Viimeksi vahvistettu: | 03/31/2020 |
| Ensimmäinen lähetys: | 05/10/2018 |
| Arvioitu ilmoittautuminen lähetetty: | 05/10/2018 |
| Ensimmäinen lähetetty: | 05/22/2018 |
| Viimeisin päivitys lähetetty: | 04/25/2020 |
| Viimeisin päivitys lähetetty: | 04/27/2020 |
| Todellinen opintojen alkamispäivä: | 01/31/2020 |
| Arvioitu ensisijainen valmistumispäivä: | 11/30/2021 |
| Arvioitu tutkimuksen valmistumispäivä: | 11/30/2021 |
Ehto tai tauti
Interventio / hoito
Drug: Febuxostat 40mg
Drug: Benzbromarone 50mg
Other: Control
Vaihe
Varren ryhmät
| Varsi | Interventio / hoito |
|---|---|
| Experimental: Febuxostat 40mg Febuxostat 40mg orally per day | Drug: Febuxostat 40mg Febuxostat 40 mg orally per day plus dietary control only |
| Active Comparator: Benzbromarone 50mg Benzbromarone 50mg orally per day | Drug: Benzbromarone 50mg Benzbromarone 50mg orally per day plus dietary control only |
| Other: Control Dietary control only | Other: Control Dietary control only |
Kelpoisuusehdot
| Tutkimukseen soveltuvat iät | 40 Years Vastaanottaja 40 Years |
| Sukupuolet, jotka ovat kelpoisia tutkimukseen | All |
| Hyväksyy terveelliset vapaaehtoiset | Joo |
| Kriteeri | Inclusion Criteria (all of the four criteria) 1. Aged between 40-75 years 2. Metabolic syndrome 3. Hyperuricemia, defined as a serum uric acid level of 7 mg/dl or more in men or 6 mg/dl or more in females, with a history of hyperuricemia within a year; or a serum uric acid level of 8 mg/dl or more in men or 7 mg/dl or more in females and it is hardly expected to be modified by dietary control; or persistent hyperuricemia after dietary control for 3 months 4. Not take any of urate-lowering therapies (benzbromarone, allopurinol, or febuxostat) Exclusion Criteria: 1. pregnancy 2. hypersensitivity to febuxostat or benzbromarone 3. acute gout 4. a history of urinary tract stone 5. chronic kidney disease stage IV or V 6. valvular heart disease with moderate or severe regurgitation 7. left ventricular ejection fraction of 40% or less 8. hypertrophic cardiomyopathy or dilated cardiomyopathy or infiltrative cardiomyopathy or constrictive cardiomyopathy 9. a history of congenital heart disease 10. a history of pulmonary hypertension 11. chronic atrial fibrillation or significant arrhythmia 12. a history of intracardiac device implantation 13. uncontrolled hypertension (systolic blood pressure > 160mm Hg or diastolic blood pressure > 100 mm Hg) 14. alanine Aminotransferase > 3 times upper limit) 15. acute infection 16. suspected or diagnosed with malignancy 17. a history of autoimmune disease 18. limited to or dependent on daily activities 19. life expectancy less than a year 20. Acute coronary syndrome or received a percutaneous coronary intervention or received a coronary artery graft bypass surgery or stroke within 3 months 21. Diabetes with insulin treatment or glucagon-like peptide 1 receptor agonist treatment 22. Anemia (hemoglobin < 11 mg/dl in mem or <10mg/dl in women) |
Tulokset
Ensisijaiset tulosmittaukset
1. Change of average E/e' [At day1 and at week 12]
2. Difference of average E/e' [At day1 and at week 12]
3. Automate office blood pressure (AOBP) [At day1 and at week 12]
Toissijaiset tulosmittaukset
1. Change of xanthine oxidase activity [At day1 and at week 12]
2. Difference of xanthine oxidase activity [At day1 and at week 12]
3. Change of left ventricular mass index [At day1 and at week 12]
4. Difference of left ventricular mass index [At day1 and at week 12]
5. Change of tumor necrosis factor alpha [At day1 and at week 12]
6. Difference of tumor necrosis factor alpha [At day1 and at week 12]
7. Change of high-sensitivity interleukin-6 [At day1 and at week 12]
8. Difference of high-sensitivity interleukin-6 [At day1 and at week 12]
9. Change of thioredoxin [At day1 and at week 12]
10. Difference of Thioredoxin [At day1 and at week 12]
11. Change of fibroblast growth factor 23 [At day1 and at week 12]
12. Difference of fibroblast growth factor 23 [At day1 and at week 12]
13. Change of Dickkopf-related protein 3 [At day1 and at week 12]
14. Difference of Dickkopf-related protein 3 [At day1 and at week 12]
15. Change of galectin-3 [At day1 and at week 12]
16. Difference of galectin-3 [At day1 and at week 12]
17. Change of ST2 [At day1 and at week 12]
18. Difference of ST2 [At day1 and at week 12]
